Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688336's EV-to-EBITDA is ranked better than 55.58% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs SHSE:688336: 10.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunshine Guojian Pharmaceutical (Shanghai) Co's PE Ratio (TTM) for today is calculated as:
Sunshine Guojian Pharmaceutical (Shanghai) Co's share price for today is ¥42.15.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.434.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-EBITDA Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
SHSE:688336 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-EBITDA vs Biotechnology Industry
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Enterprise Value is ¥36,413 Mil.
Sunshine Guojian Pharmaceutical (Shanghai) Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,521 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a EV-to-EBITDA of 10.34 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co. This is 55% below median its historical median of 22.89. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #191 out of 430 companies in the Biotechnology industry, placing it in the top 44.4%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBITDA too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current EV-to-EBITDA of 10.34 is 55% below median its 10-year median of 22.89. The Biotechnology industry median EV-to-EBITDA is 13.02. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 10.34 is 20.6% below this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #191 out of 430 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #191 out of 430 companies for EV-to-EBITDA. This puts Sunshine Guojian Pharmaceutical (Shanghai) Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.02. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 10.34 is 20.6% below this benchmark. While the company's 10-year median is 22.89 vs. the industry median of 13.02, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current EV-to-EBITDA of 10.34 is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current EV-to-EBITDA is 10.34, which is 55% below median its own 10-year median of 22.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥68.85, compared to a current price of ¥42.15 — trading 38.8% below its estimated fair value. The current EV-to-EBITDA is 10.34, which is 55% below median its 10-year median of 22.89 and 20.6% below the Biotechnology industry median of 13.02. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current EV-to-EBITDA is 10.34 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥42.15 is trading 38.8% below its estimated GF Value™ of ¥68.85.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.
Key valuation signals for SHSE:688336:
EV-to-EBITDA: 10.34 (55% below median its 10-year median of 22.89)
GF Value™: ¥68.85 vs. price of ¥42.15 (38.8% below fair value)
Industry Position: 20.6% below the Biotechnology median (#191 of 430)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
75GF Score
Get the complete analysis for SHSE:688336
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
